Mein Warenkorb

IL-21

IL-21 Molekülinformation

Englischer NameInterleukin-21Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel4Target-AliasZa11,IL-21,CVID11,Interleukin-21 Isoform,Interleukin 21
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameInterleukin-21
Target-AliasZa11,IL-21,CVID11,Interleukin-21 Isoform,Interleukin 21
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel4
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

IL-21 Molekülhintergrund

Interleukin-21 (IL-21) is a secreted protein which belongs to the IL-15 / IL-21 family. Interleukin-21 / IL-21 belongs to a family of cytokines that bind to a composite receptor consisting of a private receptor (IL21R) and the common cytokine receptor gamma chain (gamma(C)). Interleukin-21 / IL-21 impacts a number of cell types, including CD8+ memory T cells, NK cells and subsets of CD4 memory T cells. The IL-21R is widely distributed on lympho-haematopoietic cells. IL-21 is a pleiotropic cytokine produced by CD4+ T cells in response to antigenic stimulation. Its action generally enhances antigen-specific responses of immune cells. IL-21 promotes the anti-tumor activity of CD8+ T-cells and NK cells. IL-21 exerts its effect through binding to a specific type I cytokine receptor, IL-21R, which also contains the γ chain (γc) found in other cytokine receptors including IL-2, IL-4, IL-7, IL-9 and IL-15. The IL-21/IL-21R interaction triggers a cascade of events which includes activation of the tyrosine kinases JAK1 and JAK3, followed by activation of the transcription factors STAT1 and STAT3.

IL-21 Molekülalias

IL21,Za11,Interleukin-21

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
AvizakimabBOS-161721Phase 2 ClinicalMedimmune, Boston Pharmaceuticals IncLupus Erythematosus, Systemic
Details
hV-01hV-01Phase 2 ClinicalHangzhou Converd Co LtdSarcoma 180; Solid tumours; Uterine Cervical Neoplasms
Details
IL-21 mab (Lilly)Phase 1 ClinicalEli Lilly And CompanyImmune System Diseases
Details
CD-001CD-001Phase 1 ClinicalCD (Suzhou) Biopharma Co LtdSolid tumours; Hematologic Neoplasms; Neoplasms
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns